Isotechnika updates investors on planned merger with Aurinia

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have updated investors on their proposed merger to create a global nephrology company. The companies have now executed a definitive tripartite agreement with ILJIN Life Science. Subject to the successful completion of the proposed merger, the combined company will re-acquire full rights to voclosporin for autoimmune indications, [...]

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

Tweet A $255-million development partnership between Takeda Pharmaceutical and Resolve Therapeutics to develop compounds for the treatment of lupus and other autoimmune diseases highlights the potential of a merger between Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals to develop Isotechnika’s voclosporin drug for lupus nephritis. Resolve’s lead compound, RSLV-132, will begin clinical development later this year. [...]

Isotechnika merger with Aurinia to create nephrology leader

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have signed a binding term sheet to merge and create a premier clinical-stage pharmaceutical company focused on the global nephrology market. Aurinia is a spin-out from Vifor Pharma, the pharmaceutical arm of Swiss-based Galenica Group. Aurinia’s current leadership team is comprised primarily of former senior managers, directors [...]

ILJIN withdraws damage claims against Isotechnika

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” [...]

Isotechnika’s NICAMs effective against Hepatitis C virus

Tweet Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the NIH’s National Institute of Allergy and Infectious Diseases. Several NICAM compounds were tested for cross genotype activity using quantitative polymerase chain reaction in HCV replicons, [...]

Isotechnika receives partial award in ICC arbitration

Tweet Isotechnika Pharma (TSX:ISA) has received a partial award from the International Chamber of Commerce Court of Arbitration regarding its right to terminate a development, distribution and license (DDL) agreement with ILJIN Life Sciences of South Korea. The partial award provides that the DDL has not been terminated and the company’s contractual relationship with ILJIN [...]

Isotechnika highlights upcoming milestones in Q3 report

Tweet Isotechnika Pharma (TSX:ISA) expects a decision shortly from the International Chamber of Commerce (ICC) Court of Arbitration on its right to terminate a development, distribution and license agreement with ILJIN Life Science Co. Isotechnika made the disclosure in its third quarter report. It terminated the accord with ILJIN last January. In addition, Isotechnika partner [...]

Isotechnika’s NICAMs demonstrate anti-viral activity

Tweet Isotechnika Pharma (TSX: ISA) announced positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (NICAMs) through the contract testing laboratories of the National Institute of Allergy and Infectious Disease, which is part of the NIH. NICAMs are an emerging novel class of multifunctional drugs showing promise as antiviral, [...]

Isotechnika arranges private placement

Tweet Isotechnika Pharma (TSX:ISA) intends to complete a non-brokered private placement of up to 21.25 million units at a price of four cents a unit for total gross proceeds of $850,000. Each unit will consist of one common share and one warrant exercisable at five cents for a period of two years from closing. Proceeds [...]

Isotechnika gets added Canadian funding for NICAMs

Tweet Isotechnika Pharma (TSX:ISA) has received approval for additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program. NRC-IRAP previously assisted Isotechnika in the discovery of a series of NICAMs that were shown to be potent inhibitors of a class of proteins called cyclophilins. Research [...]

Next Page »